ライフサイエンスコーパス: disease-free survival rate

1 r reduced responses to therapy and decreased disease-free survival rate.

2 axillary nodes have a significantly improved disease-free survival rate.

3 Patients with stage III disease, had a 60% disease-free survival rate.

4 of local and distant recurrence, and 5-year disease-free survival rates.

5 with 5-year overall (54% v 14%, P = .07) and disease-free survival rates (32% v 18%, P = .039) higher

6 , local recurrence (4% vs 5%, P = 0.98), and disease-free survival rate (72% vs 68%, P = 0.63) betwee

7 e of T+29C polymorphism had a reduced 5-year disease-free survival rate (75.6% for T/C, and 78.2% for

8 The 3-year overall and disease-free survival rates after laparoscopic liver res

9 The 5-year overall and disease-free survival rates after laparoscopic liver res

10 g mediators (SPM) called resolvins increases disease-free survival rates and prevents metastasis afte

11 The estimated 1-year and 2-year disease-free survival rates are 62% and 46%, respectivel

12 The estimated disease-free survival rates are approximately equivalent

13 lete remissions providing 5-year overall and disease-free survival rates as high as those reported fo

14 The estimated disease-free survival rate at 10 years was 98.7%.

15 median follow-up of 67 months, the estimated disease-free survival rate at 5 years was 86.6% in the t

16 Complete responders had high disease-free survival rates at 2 years in the IMbrave150

17 Disease-free survival rates at 5 and 10 years were 34% a

18 The estimated disease-free survival rates at 5 years were 75% among pa

19 RV-infected mice had significantly increased disease-free survival rate compared to WT RRV-infected B

20 patients with TAD demonstrated an increased disease-free survival rate compared with the SLNB group,

21 (+/- 4%) 5-year and an 84% (+/- 12%) 10-year disease-free survival rate, compared with a 5-year disea

22 s with resected gastric cancer with a 2-year disease-free survival rate (DFS) of 52%.

23 The disease-free survival rate difference was 0.3% (favoring

24 The 2-year disease-free survival rate (excluding metachronous contr

25 Tissue microarray analysis showed that the disease-free survival rate for patients with high-expres

26 The median survival and disease-free survival rate for the patients with residua

27 melanoma, the mean (+/-SE) estimated 5-year disease-free survival rate for the population was 78.3+/

28 short-term efficacy in terms of biochemical disease-free survival rate for unifocal disease, and rat

29 The median survival and disease-free survival rates for all patients were 25.8 m

30 The disease-free survival rates for HCCA and PCCA were 85% (

31 One-, 3-, and 5-year disease-free survival rates for the entire population we

32 th anal canal carcinoma; however, the 5-year disease-free survival rate from concurrent fluorouracil/

33 The 24-month disease-free survival rate from time of CR was 90.9% in

34 The 5-year overall and disease-free survival rates from transplantation were 77

35 ion of axillary surgery, the 5-year invasive disease-free survival rate had to be at least 85%, and t

36 in high complete remission rates, long-term disease-free survival rates have remained disappointingl

37 The 8-year disease-free survival rate in AJCC stage I patients whos

38 verall and after induction chemotherapy) and disease-free survival rate in patients who received mult

39 Chemotherapy improves long-term disease-free survival rates in high-risk patients with r

40 Overall and disease-free survival rates in the good risk group were

41 ear overall survival rate is 81%, the 4-year disease-free survival rate is 80%, and the 4-year cumula

42 e-free survival rate, compared with a 5-year disease-free survival rate of 29% (+/- 30%) for those wh

43 We assumed a 3-year invasive-disease-free survival rate of 91.8% with pertuzumab and

44 cal margin, and low CEA levels have a 5-year disease-free survival rate of more than 30%.

45 form of surgery offers a 5-year biochemical disease-free survival rate of no better than 50%.

46 ted significant inverse correlation with the disease-free survival rate of patients and emerged as an

47 The 5-year disease-free survival rate of the definitive resection (

48 ) macrophages that were associated with 5-yr disease-free survival rates of 27.8% and 0.2%, respectiv

49 at AYA patients have improved outcomes, with disease-free survival rates of 60% to 70%, when treated

50 sponse rates of 85% or greater and long-term disease-free survival rates of 70% or greater.

51 deaths in the observation group, with 5-year disease-free survival rates of 75% and 58% (P =.0003 una

52 rs, the cross-over strategy yielded absolute disease-free survival rates of 83.7% and 67.6% for node-

53 rgroup trial 0116, prolonged the overall and disease-free survival rates of patients after a curative

54 Disease-free survival rates of patients with MMR-deficie

55 a failure (after > or = 1 year), the 5-year disease-free survival rate on the adjuvant goserelin arm

56 ata have shown no significant differences in disease-free survival rates or overall survival rates be

57 its independent significance for overall and disease-free survival rates (P = 0.045 and 0.006, respec

58 D had a significantly lower 3-year Parkinson disease-free survival rate than comparison subjects (P <

59 ontrol rates to be 93.1%; 5-year and 10-year disease-free survival rates to be 75.7% and 71.0%, respe

60 The 3-year disease-free survival rate was 15% (95% CI, 9% to 24%).

61 rgery exceeded 5 years; the estimated 5-year disease-free survival rate was 23%.

62 The 3-year disease-free survival rate was 40%.

63 The 5-year disease-free survival rate was 44%.

64 hereas in patients with melastatin loss, the disease-free survival rate was 51% +/- 8%.

65 Six-year disease-free survival rate was 55% for AS + RT and 65% f

66 patients with stage III disease, the 5-year disease-free survival rate was 56% for stage III patient

67 The 5-year disease-free survival rate was 60% (95% confidence inter

68 The 2-year disease-free survival rate was 66%, and median disease-f

69 al 5-year overall survival rate was 81%; the disease-free survival rate was 75% and the local recurre

70 n stage I patients with melastatin loss, the disease-free survival rate was 77% +/- 15% (median +/- S

71 e patients (19%) had relapsed, the actuarial disease-free survival rate was 78% (95% confidence inter

72 The 5-year disease-free survival rate was 88%.

73 fusely expressed melastatin mRNA, the 8-year disease-free survival rate was 90% +/- 7%, whereas in pa

74 The estimated 5-year invasive disease-free survival rate was 91.9% (95% confidence int

75 The 2-year invasive disease-free survival rate was 93.9% (95% CI 92.4-95.2)

76 The 5-year disease-free survival rate was 95% (95% confidence inter

77 The 5-year disease-free survival rate was four-fold greater for pat

78 No RT (83%) patients (p = 0.10), whereas the disease-free survival rate was significantly worse for P

79 Five-year disease-free survival rates were 39% in the FU plus LV a

80 The 12-month disease-free survival rates were 47.1% and 64.0%, respec

81 Overall 5-year and disease-free survival rates were 51% and 46%, respective

82 The 1- and 3-year disease-free survival rates were 64.5% and 19%, respecti

83 -Meier estimated 5-year overall survival and disease-free survival rates were 66% and 53%, respective

84 of initial resection, ITT 5-year overall and disease-free survival rates were 69% and 60%, respective

85 The local recurrence and 5-year disease-free survival rates were 7% and 78%, respectivel

86 The estimated 2-year overall survival and disease-free survival rates were 71.6% and 53.5%, respec

87 Respective 5-year disease-free survival rates were 74% and 24% (P =.0001).

88 Disease-free survival rates were 74.8% in the laparoscop

89 The actuarial 7-year disease-free survival rates were 81% and 87% (P = 0.764)

90 ctively (p = 0.02); the corresponding 5-year disease-free survival rates were 81.9%, 78.1%, and 76.6%

91 urrence rate was 4% and overall survival and disease-free survival rates were 83% and 70% at 5 years,

92 The 5-year disease-free survival rates were 87% in patients with pr

93 a median follow-up of 61 months, the 5-year disease-free survival rates were 87% in patients without

94 The 1-, 3-, and 5-year disease-free survival rates were as follows: 77%, 41%, a

95 Disease-free survival rates were assessed from the date

96 However, the 10-y disease-free survival rates were better for the SLNB gro

97 Local recurrence rates were very low and disease-free survival rates were correspondingly high in

98 homas (884 patients), the 5-year and 10-year disease-free survival rates were reported to be 86.4% an

99 The 5-year overall and disease-free survival rates were significantly higher in

100 Mean (+/- SE) 10-year disease-free survival rates were significantly improved

101 36 months, 3-year overall survival (OS) and disease-free survival rates were significantly lower in

102 The overall survival and disease-free survival rates were significantly worse for

103 BRCA1 and BRCA2 alterations showed elevated disease-free survival rates when carboplatin was added (

104 ear OS of approximately 85%; however, 5-year disease-free survival rates with S plus CT were 78% (T1-

105 n is associated with an actuarial 51% 5-year disease-free survival rate, with a median follow-up time